TNFRSF1A and acute graft versus host disease: For example, it was shown that differently combining soluble markers ST2, Reg3α, TNFR1, and IL-2Rα (with the ST2 and Reg3α combination yielding the best results) could stratify patients in high and low risk groups for non-relapse mortality (NRM), response to treatment, and onset of lethal acute GVHD post-HSCT (14, 15).